AVAI (Avai Bio) Return-on-Tangible-Asset: -2,561.85% (As of Dec. 2025)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.14
! 3 Warning Signs
View Full Analysis

What is Avai Bio Return-on-Tangible-Asset?

Avai Bio AVAI -3.93% 24 Return-on-Tangible-Asset is -2,561.85% as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,881 Software companies, Avai Bio ranks worse than 99.31% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Avai Bio's annualized Net Income for the quarter that ended in Dec. 2025 was $-2.22 Mil. Avai Bio's average total tangible assets for the quarter that ended in Dec. 2025 was $0.09 Mil. Therefore, Avai Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -2,561.85%.

The historical rank and industry rank for Avai Bio's Return-on-Tangible-Asset or its related term are showing as below:

AVAI' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1908.52   Med: -159   Max: -26
Current: -1641.72

During the past 8 years, Avai Bio's highest Return-on-Tangible-Asset was -26.00%. The lowest was -1908.52%. And the median was -159.00%.

AVAI's Return-on-Tangible-Asset is ranked worse than
99.31% of 2881 companies
in the Software industry
Industry Median: 2.02 vs AVAI: -1641.72

Avai Bio  (OTCPK:AVAI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Avai Bio Return-on-Tangible-Asset Related Terms


Avai Bio Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Avai Bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio Return-on-Tangible-Asset Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Return-on-Tangible-Asset
Get a 7-Day Free Trial -71.31 -26.00 -159.00 -1,908.52 -1,092.82

Avai Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,609.52 3,067.77 -3,454.87 -2,745.45 -2,561.85

AVAI vs IPM, RCT, LPSN: Return-on-Tangible-Asset Comparison

For the Software - Application subindustry, Avai Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avai Bio Return-on-Tangible-Asset vs Software Industry

For the Software industry and Technology sector, Avai Bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Avai Bio's Return-on-Tangible-Asset falls into.


AVAI
24GF Score
Avai Bio Inc AVAI
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio Return-on-Tangible-Asset Calculation

Avai Bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-1.142/( (0.116+0.093)/ 2 )
=-1.142/0.1045
=-1,092.82 %

Avai Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-2.216/( (0.112+0.061)/ 2 )
=-2.216/0.0865
=-2,561.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of -2,561.85% mean?
Avai Bio (AVAI) has a Return-on-Tangible-Asset of -2,561.85% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #2861 out of 2881 companies in the Software industry, placing it in the top 99.3%.
Is Avai Bio's Return-on-Tangible-Asset too high?
Avai Bio's current Return-on-Tangible-Asset is -2,561.85%. Based on the distribution chart, Avai Bio ranks #2861 out of 2881 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Return-on-Tangible-Asset compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #2861 out of 2881 companies for Return-on-Tangible-Asset. This places Avai Bio in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Software company?
The median Return-on-Tangible-Asset among Software companies is 2.02, based on 2,881 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Avai Bio and its competitors. For the Software industry, the median Return-on-Tangible-Asset is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current Return-on-Tangible-Asset is -2,561.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Return-on-Tangible-Asset of -2,561.85%. The current Return-on-Tangible-Asset is -2,561.85%. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Avai Bio (AVAI), the current Return-on-Tangible-Asset is -2,561.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price